PT  - JOURNAL ARTICLE
AU  - Jan A. Paredes
AU  - Valeria Garduño
AU  - Julian Torres
TI  - COVID-19 Related Mortality and The BCG Vaccine
AID  - 10.1101/2020.05.01.20087411
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.05.01.20087411
4099  - http://medrxiv.org/content/early/2020/05/28/2020.05.01.20087411.short
4100  - http://medrxiv.org/content/early/2020/05/28/2020.05.01.20087411.full
AB  - The coronavirus disease 2019 (COVID-19) pandemic has become a worldwide emergency. In the attempt to search for interventions that would improve outcomes, some researchers have looked at the potential benefit of BCG vaccination. These early studies have found a statistically significant reduction in COVID-19 related mortality in countries with a current universal bacille Calmette-Guérin (BCG) vaccination policy; partially explained by induced heterologous immunity. However, just as the authors themselves noted, the nature of ecological studies make them very prone to the presence of several confounders. This paper tries to answer the question as to whether a statistically significant difference in mortality rates exists between countries with differing BCG vaccination policies; while being the first to try to account for most of these confounders. We compared the number of COVID-19 related deaths per 1 million inhabitants as well as the number of deaths at the time the countries hit the 1000th COVID-19 case. Countries were divided in those which never had a BCG vaccination policy, those with a prior vaccination policy and those with a current vaccination policy. All data was gathered from publicly available sources. It was found that no statistically significant difference exists in mortality rates between countries with differing BCG vaccination policies. This result seems to reflect the notion that heterologous immunity fades with time after administration. Nevertheless, the immunostimulatory potential of the BCG vaccine might still prove useful in the development of future vaccines or other prophylactic measures.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe authors received no specific funding for this work.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:All relevant ethical guidelines have been followedAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll relevant data are within the manuscript and its Supporting Information files. http://datahelpdesk.worldbank.org/knowledgebase/articles/906519-world-bank-country-and-lending-groups http://www.bcgatlas.org https://www.worldometers.info/coronavirus/coronavirus-cases/